Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation

Liver Transplantation

Volumn 14, Issue 4, 2008, Pages 563-570

  Tsuchiya, Ayako ^a   Yazaki, Masahide ^a   Kametani, Fuyuki ^b   Takei, Yo Ichi ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; METHIONINE; PREALBUMIN; VALINE;

ABDOMINAL FAT; ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; DISEASE SEVERITY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; WILD TYPE;

ABDOMEN; ADIPOSE TISSUE; ADULT; AMYLOID NEUROPATHIES, FAMILIAL; BIOPSY, NEEDLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER TRANSPLANTATION; MALE; REMISSION, SPONTANEOUS; TIME FACTORS;

EID: 42149149817     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21395     Document Type: Article

References (32)

1. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002;58:1001-1007.
2. Connors LH, Lim A, Prokaeva T, Rokaeva T, Roskens. VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10:160-184.
3. Holmgren G, Steen L, Ekstedt J, Groth CG, Eriezon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met3O). Clin Genet 1991,40:242-246.
4. Ando Y, Tanaka Y, Nakazato, M, Bogoranericzon, Yamashita T, Tashima K, et al. Change in variant transthyretin levels in patients with familial amyloidostic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun 1995;211:354-358.
5. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-1116.
6. Bergethon PR, Sabin TD, Lewis D, Simms RW, Cohen AS, Skinner M. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 1996;47:944-951.
7. Takei Y, Ikeda S, Hashikura Y, Ikegami T, Kawasaki S. Partial-liver transplantation to treat familial amyloid poly-neuropathy: Follow-up study of 11 patients. Ann Intern Med 1999;131:592-595.
8. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000;123:1495-1504.
9. de Carvalho M, Conceição I, Bentes C, Luis MLS. Longterm quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid 2002;9:126-133.
10. Herlenius G, Wilczek HE, Larsson M, Ericzon BG; Familial Amyloidotic Polyneuropathy World Transplant Registry. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidostic polyneuropathy world transplant registry. Transplantation 2004; 1:64-71.
11. Takei Y, Ikeda S, Ikegami T, Hashikura Y, Miyagawa S, Ando Y, Japanese Liver Transplantation Society. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantation. Intern Med 2005;44:1151-1156.
12. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997;64:74-80.
13. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. Transplantation 1998;66:229-233.
14. Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun 2000; 274:702-706.
15. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007; 7:235-242.
16. Maruyama K, Ikeda S, Yanagisawa N, Nakazato M. Diagnostic value of abdominal fat aspirate in familial amyloid polyneuropathy. J Neurol Sci 1987;81:11-18.
17. Ikeda S, Nakano T, Yanagisawa N, Nakazato M, Tsukagoshi H. Asymptomatic homozygous gene carrier in a family with type I familial amyloid polyneuropathy. Eur Neurol 1992;32:308-313.
18. Shur OB, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidostic polyneuropathy. J Intern Med 1994;235:479-485.
19. Tashima K, Ando Y, Terazaki H, Yoshimatsu S, Suhr OB, Obayashi K, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 1999; 171:19-23.
20. Hazenberg BPC, Limburg PC, Bijzet J, van Rijswijk MH. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis 1999;58:96-102.
21. Shimojima Y, Morita H, Kobayashi S, Takei Y, Ikeda S. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. J Neurol (in press).
22. Benson MD. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw Hill; 2001: 5345-5378.
23. van Gameren II, Hazenberg BPC, Jager PL, Smit JW, Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 2002;9:165-174.
24. Shimojima Y, Takei Y, Tazawa K, Gono T, Fushimi T, Matsuda M, et al. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman's disease. Amyloid 2006; 13:184-186.
25. Benson MD, Liepnieks JJ, Yazaki M, Yamashita T, Hamidi Asl K, Guenther B, et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 2001;72:272-277.
26. Ishihara T, Uchino F. Pathological study on amyloidosis. Amyloid formation and resorption in Kupper cell. Recent Adv RES Res 1975; 15:145-171.
27. Dwulet F, Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial. polyneuropathy of Swedish origin. Proc Natl Acad Sci U S A 1984;81:694-698.
28. Saraiva MJM, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984;74:104-119.
29. Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 2003;28:438-442.
30. Liepnieks, JJ, Wilson DL, Benson MD. Biochemical characterization of vitreous and cardiac amyloid in IIe84Ser transthyretin amyloidosis. Amyloid 2006; 13:170-177.
31. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005; 121: 73-85.
32. Gillmore JD, Hawkins PN. Amyloidosis and the respiratory tract. Thorax 1999;54:444-451.